Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade

  title={Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade},
  author={Michael A. Postow and Robert Sidlow and Matthew D. Hellmann},
  journal={The New England Journal of Medicine},
Side Effects of Immune Checkpoint Blockade The wide range of immune-related adverse effects associated with immune checkpoint blockade can complicate this effective therapy and limit its use in patients with cancer. This review surveys the adverse effects and their management. 

Figures and Tables from this paper

Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma

This systematic review and meta-analysis evaluates the immune checkpoint inhibitor regimens used along with the incidence of adverse events reported in randomized clinical trials for treatment of

Immune-related adverse events of checkpoint inhibitors

  • J. Farkas
  • Medicine
    Nature Reviews Disease Primers
  • 2020
This PrimeView highlights the manifestations and diagnosis of immune-related adverse events caused by immune checkpoint inhibitors, and accompanies the Primer article by Ramos-Casals et al.

Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach

Understanding the role of germline genetic factors in determining individual responses to immunotherapy will deepen the understanding of immune toxicity and may lead to tools for identifying patients who are at risk.

Immune‐related adverse events in cancer patients being treated with immune checkpoint inhibitors

With the increased use of immune checkpoint inhibitors (ICI), it is essential to improve the understanding of immune‐related adverse events (irAE), and identification of patients at increased risk of irAE is needed.

Predictors of Rheumatic Immune‐Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer

To identify predictors of rheumatic immune‐related adverse events (irAEs) following immune checkpoint inhibitor (ICI) treatment for cancer, a large number of patients with a history of immune checkpoint disease were diagnosed with at least some form of cancer.

Retrospective analysis of hospital admissions due to immune checkpoint inhibitor‐induced immune‐related adverse events (irAE)

Hospital admissions secondary to immune‐related adverse events (irAE) arising from immune checkpoint inhibitors (ICI) are likely to increase with increasing use of this class of drug. We sought to

Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases

Immune checkpoint inhibitors may variably impact patients with pre‐existing autoimmune diseases as well as new patients diagnosed with these diseases.

Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China

The immune‐related adverse events in immune checkpoint inhibitors remain poorly understood, especially in a real‐world setting, and need to be understood more fully.

Management of immune checkpoint inhibitor‐related rheumatic adverse events

In this systematic review, the clinical characteristics of rheumatic irAEs are considered, including patients with pre‐existingRheumatic diseases, and the management of r hematological IRAEs is focused on.



The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.

The risk of infection among patients receiving immune checkpoint blockade is unknown, and the main risk factors were receipt of corticosteroids and/or infliximab.

Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade.

In a patient with colon cancer and a history of autoimmunity, skin and gastrointestinal toxicity developed after the receipt of pembrolizumab. Interleukin-17 blockade reversed the autoimmunity but

Thyroid abnormalities following the use of cytotoxic T‐lymphocyte antigen‐4 and programmed death receptor protein‐1 inhibitors in the treatment of melanoma

Checkpoint inhibitors are emerging as important cancer therapies but are associated with a high rate of immune side effects, including endocrinopathy, which can be harmful to the immune system.

Management of immune-related adverse events and kinetics of response with ipilimumab.

A detailed description of irAEs and recommendations for practicing oncologists who are managing them, along with the unusual kinetics of response associated with ipilimumab therapy are provided.

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.

The clinical use of immune checkpoint inhibitors is expanding rapidly and oncology practitioners will be required to recognize and manage irAEs in a growing patient population and adherence to established algorithms is recommended.

Responses to immune checkpoint inhibitors in nonagenarians

It is suggested that with close monitoring, even very elderly patients with advanced cancers and acceptable performance status may tolerate and benefit from immune checkpoint inhibitors.

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review

Comparison of irAE from the three most studied tumour types in PD-1 mAbs trials showed melanoma patients had a higher frequency of gastrointestinal and skin irAE and lower frequency of pneumonitis and other tumour-dependent irAE profiles may be identified as data emerge from ICI trials.

Opportunistic infections in patients treated with immunotherapy for cancer

The first reported case to the knowledge of an opportunistic infection in a patient treated with an immunomodulatory antibody is presented.

Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma.

A case of acute graft rejection in a kidney transplant recipient after treatment with nivolumab is described, after progression on ipilimumab.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Calcium, CRP, C-reactive protein, CT, computed tomography, ESR, sedimentation rate, and checkpoint are used to estimate the concentration of phosphorous in the sediments.